These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34746146)

  • 21. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
    van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
    J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Effects of CSF Neurogranin and
    Fan Y; Gao Y; Therriault J; Luo J; Ba M; Zhang H;
    Front Aging Neurosci; 2021; 13():667899. PubMed ID: 33986657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease.
    Baldeiras I; Santana I; Leitão MJ; Vieira D; Duro D; Mroczko B; Kornhuber J; Lewczuk P
    Alzheimers Res Ther; 2019 Jan; 11(1):2. PubMed ID: 30611311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
    Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
    Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New assay for old markers-plasma beta amyloid of mild cognitive impairment and Alzheimer's disease.
    Chiu MJ; Yang SY; Chen TF; Chieh JJ; Huang TZ; Yip PK; Yang HC; Cheng TW; Chen YF; Hua MS; Horng HE
    Curr Alzheimer Res; 2012 Dec; 9(10):1142-8. PubMed ID: 22950866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
    Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
    Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI.
    Vos SJ; van Rossum IA; Verhey F; Knol DL; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Frisoni GB; Froelich L; Nobili F; van der Flier W; Blennow K; Wolz R; Scheltens P; Visser PJ
    Neurology; 2013 Mar; 80(12):1124-32. PubMed ID: 23446677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.
    Leuzy A; Carter SF; Chiotis K; Almkvist O; Wall A; Nordberg A
    J Alzheimers Dis; 2015; 45(4):1077-88. PubMed ID: 25649653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging.
    Gupta VB; Doecke JD; Hone E; Pedrini S; Laws SM; Thambisetty M; Bush AI; Rowe CC; Villemagne VL; Ames D; Masters CL; Macaulay SL; Rembach A; Rainey-Smith SR; Martins RN;
    Alzheimers Dement (Amst); 2016; 3():18-26. PubMed ID: 27239546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Independent and Interactive Influences of the APOE Genotype and Beta-Amyloid Burden on Cognitive Function in Mild Cognitive Impairment.
    Seo EH; Kim SH; Park SH; Kang SH; Choo IH;
    J Korean Med Sci; 2016 Feb; 31(2):286-95. PubMed ID: 26839485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma Clusterin and the CLU Gene rs11136000 Variant Are Associated with Mild Cognitive Impairment in Type 2 Diabetic Patients.
    Cai R; Han J; Sun J; Huang R; Tian S; Shen Y; Dong X; Xia W; Wang S
    Front Aging Neurosci; 2016; 8():179. PubMed ID: 27516739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased intermediate M1-M2 macrophage polarization and improved cognition in mild cognitive impairment patients on ω-3 supplementation.
    Famenini S; Rigali EA; Olivera-Perez HM; Dang J; Chang MT; Halder R; Rao RV; Pellegrini M; Porter V; Bredesen D; Fiala M
    FASEB J; 2017 Jan; 31(1):148-160. PubMed ID: 27677546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype.
    Blom ES; Giedraitis V; Zetterberg H; Fukumoto H; Blennow K; Hyman BT; Irizarry MC; Wahlund LO; Lannfelt L; Ingelsson M
    Dement Geriatr Cogn Disord; 2009; 27(5):458-64. PubMed ID: 19420940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cerebrospinal fluid biomarkers for Alzheimer's disease: the role of apolipoprotein E genotype, age, and sex.
    Mehrabian S; Alexopoulos P; Ortner M; Traykov L; Grimmer T; Kurz A; Förstl H; Bickel H; Diehl-Schmid J
    Neuropsychiatr Dis Treat; 2015; 11():3105-10. PubMed ID: 26719695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in Plasma Amyloid and Tau in a Longitudinal Study of Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease.
    Chen TB; Lai YH; Ke TL; Chen JP; Lee YJ; Lin SY; Lin PC; Wang PN; Cheng IH
    Dement Geriatr Cogn Disord; 2019; 48(3-4):180-195. PubMed ID: 31991443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Type 2 diabetes mellitus and cerebrospinal fluid Alzheimer's disease biomarker amyloid β1-42 in Alzheimer's Disease Neuroimaging Initiative participants.
    Li W; Risacher SL; Gao S; Boehm SL; Elmendorf JS; Saykin AJ
    Alzheimers Dement (Amst); 2018; 10():94-98. PubMed ID: 29255789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Associations of Plasma BACE1 Level and BACE1 C786G Gene Polymorphism with Cognitive Functions in Patients with Type 2 Diabetes: A Cross- Sectional Study.
    Tian S; Huang R; Guo D; Lin H; Wang J; An K; Wang S
    Curr Alzheimer Res; 2020; 17(4):355-364. PubMed ID: 32442083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Effect of the APOE Genotype on Individual BrainAGE in Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease.
    Löwe LC; Gaser C; Franke K;
    PLoS One; 2016; 11(7):e0157514. PubMed ID: 27410431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.